What they are
Not every woman can take — or wants — hormone therapy. A growing set of non-hormonal options exists specifically for vasomotor symptoms, and this category has changed more in the last few years than in the previous two decades.
What's commonly discussed
- NK3-receptor antagonists — a newer class of daily, non-hormonal prescription medications (fezolinetant was the first FDA-approved) that work on the brain's temperature-regulation pathway, the same circuitry that drives hot flashes.
- Certain antidepressants at low doses — some SSRIs/SNRIs have evidence for reducing hot flash frequency; one low-dose SSRI is FDA-approved specifically for vasomotor symptoms. Discussing one for hot flashes is not the same as being treated for depression — a distinction many women find clarifying.
- Other prescription options — including gabapentin (often discussed when night sweats disturb sleep) and oxybutynin.
- Mind-body approaches with clinical evidence — cognitive behavioral therapy and clinical hypnosis both have trial support for reducing how bothersome vasomotor symptoms are.
Common misconceptions
The biggest one: “if I can't take hormones, nothing can help.” That was closer to true fifteen years ago; it isn't now. Another: assuming all supplements marketed for hot flashes have equivalent evidence — most have limited or mixed data, which is worth raising honestly at a visit.
What women often notice
Not guaranteed, and not everyone — educational only. Women using evidence-based non-hormonal options often report fewer or milder hot flashes and, when night sweats were disturbing sleep, better rest. Which benefit comes first varies by option — one reason the choice is individualized at a visit.
Questions you may wish to discuss
- Which non-hormonal options fit my health history and other medications?
- What benefit is realistic — fewer hot flashes, milder ones, or both?
- If sleep disruption is my main problem, does that change which option to consider first?
- Are there interactions with medications I already take?
✓ EVIDENCE SNAPSHOT
The Menopause Society's guidance on non-hormonal management identifies several options with meaningful evidence for vasomotor symptoms — including NK3-receptor antagonists, certain SSRIs/SNRIs, gabapentin, oxybutynin, cognitive behavioral therapy, and clinical hypnosis — while noting that many popular supplements lack consistent evidence.
Learn next
- Hot flashes & night sweats
- Sleep
- Systemic estrogen therapy
- Mood & anxiety
- Supplements: what the evidence says
- Testosterone therapy for women
- The North American Menopause Society (now The Menopause Society). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927–938.
- The North American Menopause Society (now The Menopause Society). The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause. 2020;27(9):976–992.
- The North American Menopause Society (now The Menopause Society). The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573–590.
- Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660–4666.
- Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
- American College of Obstetricians and Gynecologists. Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123(1):202–216.